Accelerate your Timelines in Neuroscience & Metabolic Clinical Development
Partner with a Clinical Research Organization (CRO) that specializes in managing the complexities of Neuroscience and Metabolic clinical development programs. Better Science. Superior Results.
Since 2023, we have contributed to 32 FDA approvals, representing 27% of all drug approvals in the United States.
Supporting global clinical research across all phases of drug development.
With a global footprint and deep therapeutic expertise, we support clinical research from first-in-human through late-phase development. The Lotus-ERG team includes 47 MDs and 12 PhDs/PsyDs, bringing scientific and clinical leadership to every trial we touch. Backed by experience in more than 3,400 studies, we offer the operational precision, regulatory insight, and global site access needed to accelerate development and deliver high-quality data.
Speed AND Quality:
Priority Access to ERG's Site Network
Lotus is differentiated from other CROs by our common ownership with ERG. Our highly sought-after, US-based sites include 20 wholly-owned research units, over 400 beds, nine surgical centers, and multiple Phase I units, providing access to specialized capabilities for both healthy volunteer studies and targeted patient populations in neuroscience and metabolic disease research.
This unique Lotus-ERG structure enables rapid study startup and unparalleled operational efficiency, as many of the slow-track activities associated with site initiation (contracting, legal, etc.) are already in place. The leadership, medical, and operational teams are in constant communication and Lotus-Sponsor studies are prioritized.
The team is working before the ink is dry. That’s how we accelerate timelines.
Better Together: The Advantages of a CRO and Site Network Working Together in Clinical Development
A Deeper Dive into Neuroscience Experience
Lotus has deep experience across the neuroscience disease spectrum, supporting all phases of development for novel medicines. We provide scientific leadership and have extensive experience with the neuroscience approval process.
Neuroscience Drug Approvals
Neuroscience Studies Completed
FDA Inspections Resulting in a 483
Statistics combine experience from both Lotus Clinical Research and Evolution Research Group’s network of clinical research sites.
A Deeper Dive into Metabolic Experience
ERG’s site network provides rapid access to some of the most well-respected sites in the country for metabolic research in diabetes, MASH, and obesity. Guided by a science-first approach, our Scientific Leadership Team brings extensive experience in obesity and metabolic research.
Metabolic Studies Conducted
Diabetes Studies Conducted
Obesity Studies Conducted
MASH/NAFLD Studies Conducted
FibroScan, MRI, Biopsies Present in Many Trials
Statistics combine experience from both Lotus Clinical Research and Evolution Research Group’s network of clinical research sites.
How Scientific Leadership Drives Trial Success
At Lotus Clinical Research, we do more than manage trials. We help shape them.
Our Scientific Leadership Team reviews every new protocol at the bid stage to assess the potential study risks. The team then works directly with the Sponsor and project teams to mitigate risks in advance of First-Patient-In and continues to be hands-on throughout the life of the trial. Every Lotus study is assigned a Scientific Leadership Team member from this list of clinicians, research experts, and scientists. Let us advance your molecule and bring your vision to life through our clinical and operational expertise.
Nitendra Agarwal, MD
Internal Medicine / Obesity
Glen Apseloff, MD
Abuse Liability / Clin Pharm
Sarah Atkinson, MD
Psychiatry Adult / Pediatrics
Mark Brody, MD, CPI
Neurology / AD
Keith Candiotti, MD
Anesthesiology / Pain
Andria Chastain
Psychiatry / Addiction
Andrew Cutler, MD
Psychiatry / Neurology / Addiction
Clay Dehn, MS
Metabolism / MASH / Clin Pharm / Obesity
Emanuel DeNoia, MD
Phase I / Internal Medicine
Stacy Dilzer, RN, CCRC
Clin Pharm / Renal/Hepatic
Bernadette D’Souza, MD
Psychiatry / Addiction
Judith Dunn, PhD
Drug Development / CNS
Angela Eakin, MD
Phase I / Family Medicine
Ellen Fields, MD
Drug Development / Regulatory
Ana Fuquay, MS, CCRC
Alzheimer’s Disease / Neurology
Daniel Gruener, MD
Psychiatry / Pain / Addiction
Sharon Hertz, MD
Regulatory
George Konis, MD
Psychiatry / Addiction / Internal Medicine
Romana Kulikova, MD
Neurology / Pediatrics
David Leiman, MD
Acute & Chronic Pain / Anesthesiology
Suresh Mallikaarjun, MD
Drug Development / Clin Pharm
William Martin, PhD
Drug Development / CNS
Harold Minkowitz, MD
Acute & Chronic Pain / Anesthesiology
Ashley Poole, CCRC
Psychiatry
Alexander Prezioso, MD
Obstetrics & Gynecology / Phase I
Steve Romano, MD
Drug Development / CNS
Janeen Rosales, MS, CCRC
Phase I / Special Populations
Dennis Ruff, MD
Phase I / Internal Medicine
Sherwyn Schwartz, MD
Endocrinology / MASH / Obesity
Adam Smith, PhD, MBA
Psychiatry / Neurology
Stephen Thein, PhD
Sleep / Alzheimer’s Disease
Erin Tireman, PysD
Rater Training / CNS / Psychedelics / Addiction
Daniel Umbricht, MD
Translational Medicine / CNS
Kimberly Vanover, PhD
Drug Development / CNS
Richard Walovitch, MD
Imaging / Pharmacology
James Whalen, MD
Psychiatry
